Response during the open-label phase was defined as a CGI Severity of Illness item score of ≤3 and a HAM-D-21 total score of ≤10 at the day 56 evaluation. Mild sinus tachycardia was reported in two of the other patients.Actions taken to treat the overdose included no treatment, hospitalization and symptomatic treatment, and hospitalization plus treatment with activated charcoal. ... Studies have shown that Plexus may cause more harm than good. One patient who ingested 2.75 g of venlafaxine was observed to have two generalized convulsions and a prolongation of QTc to 500 msec, compared with 405 msec at baseline. Non- clinical studies have demonstrated that venlafaxine and its active metabolite, ODV, are potent and selective inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake.Venlafaxine and ODV have no significant affinity for muscarinic-cholinergic, HThe effect of venlafaxine on the QT interval was evaluated in a randomized, double-blind, placebo- and positive-controlled three-period crossover thorough QT study in 54 healthy adult subjects.

The difference between observed and expected growth rates was larger for children (< 12 years old) than for adolescents (≥ 12 years old).Decreased appetite (reported as treatment-emergent anorexia) was more commonly observed in Effexor XR treated patients versus placebo-treated patients in the premarketing evaluation of Effexor XR for MDD, GAD, and SAD (see Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine therapy have been rarely reported. Cases of elevated blood pressure requiring immediate treatment have been reported with Effexor XR. However, the 75 and 150 mg per day doses were not as consistently effective as the highest dose (study 1). The complete text of the Medication Guide is reprinted at the end of this document.Patients should be advised of the following issues and should be asked to alert their prescriber if these occur while taking Effexor XR.Advise patients, their families and caregivers to look for the emergence of suicidality, worsening of depression, and other psychiatric symptoms (anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, psychomotor restlessness, hypomania, mania, other unusual changes in behavior), especially early during treatment and when the dose is adjusted up or down. Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%). YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1-800-FDA-1088.Keep Effexor XR and all medicines out of the reach of children.venlafaxine hydrochloride capsule, extended releasevenlafaxine hydrochloride capsule, extended releasevenlafaxine hydrochloride capsule, extended releaseWe comply with the HONcode standard for trustworthy health information -

Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported.Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants.


Sustained blood pressure elevation can lead to adverse outcomes. Effexor XR (venlafaxine hydrochloride) extended-release capsules are indicated for the treatment of major depressive disorder (MDD). The concomitant use of Effexor XR with tryptophan supplements is not recommended Serotonin release by platelets plays an important role in hemostasis. In patients undergoing hemodialysis or with severe renal impairment (CLcr < 30 mL/min), the total daily dose should be reduced by 50% or more. Patients not responding to the initial 75 mg per day dose may benefit from dose increases to a maximum of 225 mg per day.
Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Effexor XR treatment for up to 8 weeks and up to 6 months in premarketing placebo-controlled GAD trials was associated with mean final on-therapy increases in serum cholesterol concentration of approximately 1.0 mg/dL and 2.3 mg/dL, respectively while placebo subjects experienced mean final decreases of 4.9 mg/dL and 7.7 mg/dL, respectively.